Identifying Differences in Risk Factors for Depression and Anxiety in Pediatric Chronic Disease: A Matched Cross-Sectional Study of Youth with Lupus/Mixed Connective Tissue Disease and Their Peers with Diabetes - 24/11/15
, Pamela Weiss, MD, MSCE 1, 2, 4, Knashawn Morales, ScD 4, Marsha Gerdes, PhD 3, 5, Melissa Rearson, MSN, CRNP 6, Michelle Vickery, MPH 2, 3, Ron Keren, MD, MPH 2, 4, 5Abstract |
Objective |
To investigate differences in risk factors for depression and anxiety, such as central nervous system involvement in systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD), by comparing youth with SLE/MCTD to peers with type 1 diabetes mellitus (T1D).
Study design |
We conducted a cross-sectional study of 50 outpatient pairs, ages 8 years and above, matching subjects with SLE/MCTD and T1D by sex and age group. We screened for depression, suicidal ideation, and anxiety using the Patient Health Questionnaire-9 and the Screen for Childhood Anxiety Related Emotional Disorders, respectively. We collected parent-reported mental health treatment data. We compared prevalence and treatment rates between subjects with SLE/MCTD and T1D, and identified disease-specific risk factors using logistic regression.
Results |
Depression symptoms were present in 23%, suicidal ideation in 15%, and anxiety in 27% of participants. Compared with subjects with T1D, subjects with SLE/MCTD had lower adjusted rates of depression and suicidal ideation, yet poorer rates of mental health treatment (24% vs 53%). Non-White race/ethnicity and longer disease duration were independent risk factors for depression and suicidal ideation. Depression was associated with poor disease control in both groups, and anxiety with insulin pump use in subjects with T1D.
Conclusion |
Depression and anxiety are high and undertreated in youth with SLE/MCTD and T1D. Focusing on risk factors such as race/ethnicity and disease duration may improve their mental health care. Further study of central nervous system and other disease-related factors may identify targets for intervention.
Le texte complet de cet article est disponible en PDF.Keyword : CHOP, CNS, HbA1c, MCTD, PHQ-9, QOL, SDI, SLE, SLEDAI, T1D
Plan
| Funded by the National Institutes of Health (5T32HD060550-03 [to A.K.]), US Health Resources and Services Administration (D34HP24459), Center of Excellence for Diversity in Health Education and Research, Perelman School of Medicine, US Health Resources and Services Administration (institutional grant D34HP24459 [to A.K.]), and Lupus Foundation of America Tri-State Chapter Anna Louise Harmon Preceptorship (to A.K.). The authors declare no conflicts of interest. |
Vol 167 - N° 6
P. 1397 - décembre 2015 Retour au numéro
Article précédent
- Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study
- Susan R. Rose, Grafton Reeves, Robert Gut, John Germak
- Primary Care Providers' Initial Evaluation of Children with Global Developmental Delay: A Clinical Vignette Study
- Beth A. Tarini, Brian J. Zikmund-Fisher, Howard M. Saal, Laurie Edmondson, Wendy R. Uhlmann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?